ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3124

Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene

Teresina Laragione1, Percio Gulko1 and Max Brenner2, 1Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Genetic Biomarkers, joint damage, pathogenesis and synovitis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Genetics, Genomics and Proteomics II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:  Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but disease discordant DA (arthritis-susceptible) and ACI (resistant) rats. DA.ACI(Cia25/Pia42) congenic rats were significantly protected in both Pristane and Collagen-induced arthritis (PIA and CIA) compared with DA. This study aimed at positionally identifying the gene accounting for Cia25/Pia42 gene.

Methods: Recombinant subcongenics covering the Cia25/Pia42 interval were generated by backcrossing the original congenic strain with DA using a genotype-guided strategy. Recombinants sharing identical intervals were then intercrossed to homozygozity. PIA was induced in 8-12 week-old subcongenic rats and disease scored for 31 days using a system that correlates with histological damage. Fibroblast-like synoviocytes (FLS) from rats and patients with rheumatoid arthritis (RA) were studied in in vitro invasion assays previously shown to correlate with radiographic damage.

Results:  Analyses of 12 different recombinant (R) subcongenic strains reduced the gene-containing interval from 33Mb to a 1.2MB region contained within subcongenic R6. R6 subcongenics had significantly 92% lower median arthritis severity score compared with DA (P<0.001) and were significantly protected from developing cartilage or bone damage (P<0.002). Sequencing of the 36 genes in the 1.2MB critical interval identified three genes with amino-acid changing SNPs with predicted protein functional consequences based on SIFT and PolyPhen2 analyses. These three genes were expressed in FLS from arthritic rats and patients with rheumatoid arthritis (RA). Huntingtin-interacting protein 1 (Hip1), a gene implicated in clathrin-mediated endocytosis, was one of these genes and was expressed in increased levels in DA FLS compared with R6. FLS from protected DA.ACI(Cia25/Pia42) subcongenic R6 were less invasive than those from DA rats, suggesting that the Cia25/Pia42 gene operates via the regulation of FLS invasion. siRNA Hip1 significantly reduced the invasive properties of FLS obtained from DA rats and from patients with RA. Hip1 knock-out mice were obtained and were protected in KRN serum-induced arthritis, confirming the importance of this gene in arthritis.

Conclusion:  Hip1 is a new arthritis severity and joint damage gene that mediates disease at least in part via the regulation of the invasive properties of FLS. The identification of this new gene is the first step towards developing new therapies and a new prognostic biomarker for RA.


Disclosure: T. Laragione, None; P. Gulko, None; M. Brenner, None.

To cite this abstract in AMA style:

Laragione T, Gulko P, Brenner M. Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/huntingtin-interacting-protein-1-hip1-is-a-new-arthritis-severity-gene/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/huntingtin-interacting-protein-1-hip1-is-a-new-arthritis-severity-gene/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology